Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.42 |
| ▸ | KLK8 | O60259 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.41 |
| ▸ | KLK14 | Q9P0G3 | 4/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199604 | 0.91 | SGMS2 (0.45) | LRRK2SGMS2CYP11B1CYP11B2KLK8 | |
| SCHEMBL2196441 | 0.80 | BRD4 (0.44) | CDK9KMT2A | |
| SCHEMBL2196789 | 0.79 | CDC7 (0.46) | SGMS2HTT | |
| SCHEMBL2197617 | 0.79 | BRD4 (0.41) | CDK9KMT2AMAPT | |
| SCHEMBL2197053 | 0.79 | BRD4 (0.47) | SGMS2HTT | |
| SCHEMBL2198985 | 0.78 | MAPT (0.47) | CDK9KMT2AMAPTHTT | |
| SCHEMBL2199606 | 0.78 | BRD4 (0.41) | CDK9KMT2AMAPT | |
| SCHEMBL2200320 | 0.78 | BRD4 (0.41) | CDK9MAPT | |
| SCHEMBL2200873 | 0.78 | BRD4 (0.41) | CDK9KMT2AMAPT | |
| SCHEMBL2197511 | 0.77 | BRD4 (0.46) | CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | LRRK2 1146/4885SGMS2 4779/4885CDK9 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.